NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Price, News & Analysis

Arbutus Biopharma logo
$4.04 -0.01 (-0.12%)
As of 03:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Arbutus Biopharma Stock (NASDAQ:ABUS)

Advanced

Key Stats

Today's Range
$3.97
▼
$4.09
50-Day Range
$3.65
▼
$5.18
52-Week Range
$3.50
▼
$5.45
Volume
1.10 million shs
Average Volume
2.94 million shs
Market Capitalization
$618.53 million
P/E Ratio
3.57
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection. Its research programs include RNA interference (RNAi) therapies, immune-based treatments and capsid assembly inhibitors, which target different aspects of the virus and the body’s response to infection.

The company’s investigational portfolio includes imdusiran, an RNAi therapeutic designed to reduce hepatitis B surface antigen, as well as other HBV drug candidates at various stages of development. Arbutus also develops drug-delivery technologies, including lipid nanoparticles and GalNAc-based approaches.

Arbutus adopted its current name in 2015 following the merger of Tekmira Pharmaceuticals and OnCore Biopharma. The company’s research and development efforts remain centered on advancing potential therapies for people with chronic HBV infection.

AI Generated. May Contain Errors.

Arbutus Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

ABUS MarketRank™: 
1.338457460905 of 5 stars

Arbutus Biopharma scored higher than 27% of companies evaluated by MarketBeat, and ranked 775th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arbutus Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Arbutus Biopharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Arbutus Biopharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arbutus Biopharma is 3.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.02.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arbutus Biopharma is 3.57, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.24.

  • Price to Book Value per Share Ratio

    Arbutus Biopharma has a P/B Ratio of 7.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    12.53% of the float of Arbutus Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Arbutus Biopharma has a short interest ratio ("days to cover") of 9.14.
  • Change versus previous month

    Short interest in Arbutus Biopharma has recently decreased by 19.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Arbutus Biopharma does not currently pay a dividend.

  • Dividend Growth

    Arbutus Biopharma does not have a long track record of dividend growth.

  • News Sentiment

    Arbutus Biopharma has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.90% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arbutus Biopharma's insider trading history.
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABUS Stock News Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Headlines

ABUS Stock Analysis - Frequently Asked Questions

Arbutus Biopharma's stock was trading at $4.81 on January 1st, 2026. Since then, ABUS stock has decreased by 16.3% and is now trading at $4.0250.

Arbutus Biopharma Corporation (NASDAQ:ABUS) posted its earnings results on Tuesday, November, 10th. The biopharmaceutical company reported $0.30 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.32. The biopharmaceutical company earned $299 thousand during the quarter, compared to analyst estimates of $1 million. Arbutus Biopharma had a net margin of 121.17% and a trailing twelve-month return on equity of 129.12%.

Arbutus Biopharma's Board of Directors initiated a stock buyback program on Friday, August 21st 2026, which allows the company to repurchase outstanding shares, according to EventVestor. This allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company's management believes its stock is undervalued.

Top institutional shareholders of Arbutus Biopharma include Two Seas Capital LP (4.11%), State Street Corp (3.57%), Goldman Sachs Group Inc. (1.68%) and First Trust Advisors LP (0.35%).
View institutional ownership trends
.

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Tesla (TSLA), NIO (NIO), Sorrento Therapeutics (SRNE), Plug Power (PLUG), Moderna (MRNA), Inovio Pharmaceuticals (INO) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/10/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ABUS
CIK
1447028
Employees
19
Year Founded
2005

Profitability

EPS (Trailing Twelve Months)
$1.13
Trailing P/E Ratio
3.57
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$33.50 million
Net Margins
121.17%
Pretax Margin
121.17%
Return on Equity
129.12%
Return on Assets
89.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.40
Quick Ratio
81.42

Sales & Book Value

Annual Sales
$14.08 million
Price / Sales
43.93
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.56 per share
Price / Book
7.21

Miscellaneous

Outstanding Shares
153,290,000
Free Float
122,788,000
Market Cap
$618.53 million
Optionable
Optionable
Beta
0.84

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:ABUS) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners